Safety Study Using Photodynamic Therapy Light Therapy for Patients With Chest Wall Progression of Breast Cancer and Satellite Metastases of Melanoma

Inclusion Criteria: * Patients \> 18 years of age, with primary or metastatic cutaneous tumors that have been previously irradiated. * Patients must have a target lesion and normal peri-umbilical skin that can be covered by the fiber-optic mesh used to deliver CLIPT (10 x 10 cm for Target lesion, and 1 x 1 cm for Control site). * Patients must have a target lesion in a location other than the hands, feet, genitals, or face. Lesions in those locations will be excluded. * Patients must sign informed consent. Exclusion Criteria: * Patients must not have received any systemic anti-cancer therapy within 30 days prior to enrolling in this study. * Patients must not have received radiation therapy to the target site within 60 days of enrolling on this study. * Patients with medical conditions associated with photosensitivity, such as cutaneous porphyria or a collagen vascular disease, or with known allergies to porphyrins will be excluded. * Pregnant and nursing patients will be excluded. Women of child-bearing potential must have a negative serum or urine pregnancy test prior to enrollment. * Patients taking medications known to cause photosensitivity (tetracyclines, sulfonamides, phenothiazines, sulfonylurea hypoglycemic agents, thiazide diuretics, griseofulvin, and fluoroquinolones) will be excluded. * Laboratory values (Note: these are provided by the potential patient): * Absolute neutrophil count \> 1000. * Patients with severe hepatic dysfunction (total bilirubin, AST, or …